Case Clinical Trials Unit

描述(由申请人提供)：Case临床试验中心(CTU)由四个高效的临床研究站点组成：Case/UHC和克利夫兰的Metro Health医疗中心，辛辛那提大学和坎帕拉的联合临床研究中心。这四个CRS站点中的每一个都是表现最好的ACTG治疗试验站点，具有出色的收益、出色的绩效评估和在网络中的主要领导作用，它是科学生产力。CTU的一个关键主题是我们的临床研究组合与我们的基础研究和翻译研究计划的密切联系。因此，案例CTU的四个CRS站点为企业带来了全面的研究计划。由在各自领域处于国内和国际领先地位的教员领导，这些单位准备为ACTG瞄准的每个优先领域做出实质性贡献：炎症/末端器官疾病、治疗、肝炎和结核病。自该网络建立以来，CASE/UHC CRS也一直是MTN的富有成效的成员，并提议在MTN中开展过去10年来一直在开发的一种高效杀微生物剂候选物(5P12-RANTES)的研究。CASE/UHC和JCRC网站都为纳入HVTN提供了强有力的理由。CASE/UHC一直在与HVTN 505上的网络合作，并开发了一个示范推广计划，将这一高优先级HVTN试验的登记人数增加了一倍以上。辛辛那提大学CRS是一家高效、管理良好的CRS，自1987年以来一直为ACTG进行临床和翻译研究。JCRC是非洲第一个艾滋病毒疫苗试验的地点，它随时可以接触到定义明确的高危人群中的大量受试者，并拥有先进的基础设施，可以成为这一网络的强大贡献者。因此，组成该CTU的四个CRS站点能够为NIAID网络的治疗和预防议程提供持续的领导和贡献。

DESCRIPTION (provided by applicant): The Case Clinical Trials Unit (CTU) comprises four highly productive clinical research sites: Case/UHC and Metro Health Medical Center in Cleveland, the University of Cincinnati and the Joint Clinical Research Center in Kampala. Each of these four CRS sites is a top performing ACTG treatment trial site with excellent accruals, outstanding performance evaluations and major roles in the leadership of the network and it is scientific productivity. A key theme of this CTU is the close link of our clinical research portfolo with our basic and translational research programs. Thus the four CRS sites of the Case CTU bring a comprehensive research plan to the enterprise. Led by faculty who are national and international leaders in their fields, these units are poised to make substantive contributions to each of the priority areas targeted by the ACTG: Inflammation/End Organ Disease, Cure, Hepatitis and Tuberculosis. The Case/UHC CRS has also been a productive member of the MTN since the network began and proposes to develop studies in the MTN of a highly effective microbicide candidate (5P12-RANTES) that it has been developing for the past 10 years. Both Case/UHC and JCRC sites provide strong rationale for inclusion in the HVTN. Case/UHC has been working with the network on HVTN 505 and has developed a model outreach program more than doubling its enrollment to this high priority HVTN trial. The University of Cincinnati CRS is a highly efficient, well-managed CRS that has been conducting clinical and translational research for the ACTG since 1987. JCRC, the site of the first HIV vaccine trial in Africa, has ready access to large numbers of subjects in well-defined populations at high risk for HIV infection and has the advanced infrastructure to become a powerful contributor to this network. Thus the four CRS sites that comprise this CTU are positioned to provide sustained leadership and contribution to the treatment and prevention agenda of the NIAID Networks.